Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report

An 83-year-old man received pembrolizumab treatment after anticancer chemotherapy with gemcitabine and cisplatin for advanced bladder cancer. Pathological findings revealed invasive urothelial carcinoma with squamous differentiation before treatment. After seven courses of pembrolizumab treatment, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasegawa, Moto, Hasegawa, Go, Ikeda, Yohei, Hara, Noboru, Nishiyama, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294485/
https://www.ncbi.nlm.nih.gov/pubmed/32587697
http://dx.doi.org/10.1177/2050313X20932694
_version_ 1783546497002897408
author Hasegawa, Moto
Hasegawa, Go
Ikeda, Yohei
Hara, Noboru
Nishiyama, Tsutomu
author_facet Hasegawa, Moto
Hasegawa, Go
Ikeda, Yohei
Hara, Noboru
Nishiyama, Tsutomu
author_sort Hasegawa, Moto
collection PubMed
description An 83-year-old man received pembrolizumab treatment after anticancer chemotherapy with gemcitabine and cisplatin for advanced bladder cancer. Pathological findings revealed invasive urothelial carcinoma with squamous differentiation before treatment. After seven courses of pembrolizumab treatment, the tumor disappeared. After 15 courses of the treatment, the tumor regrew. Pathological findings revealed invasive undifferentiated urothelial carcinoma consisting of relatively small tumor cells of the same size as lymphocytes, negative for neuroendocrine markers. Programmed death-ligand 1 expressions in tumor tissue changed from positive before treatment to negative after pembrolizumab treatment.
format Online
Article
Text
id pubmed-7294485
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-72944852020-06-24 Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report Hasegawa, Moto Hasegawa, Go Ikeda, Yohei Hara, Noboru Nishiyama, Tsutomu SAGE Open Med Case Rep Case Report An 83-year-old man received pembrolizumab treatment after anticancer chemotherapy with gemcitabine and cisplatin for advanced bladder cancer. Pathological findings revealed invasive urothelial carcinoma with squamous differentiation before treatment. After seven courses of pembrolizumab treatment, the tumor disappeared. After 15 courses of the treatment, the tumor regrew. Pathological findings revealed invasive undifferentiated urothelial carcinoma consisting of relatively small tumor cells of the same size as lymphocytes, negative for neuroendocrine markers. Programmed death-ligand 1 expressions in tumor tissue changed from positive before treatment to negative after pembrolizumab treatment. SAGE Publications 2020-06-13 /pmc/articles/PMC7294485/ /pubmed/32587697 http://dx.doi.org/10.1177/2050313X20932694 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Hasegawa, Moto
Hasegawa, Go
Ikeda, Yohei
Hara, Noboru
Nishiyama, Tsutomu
Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
title Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
title_full Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
title_fullStr Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
title_full_unstemmed Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
title_short Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
title_sort emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294485/
https://www.ncbi.nlm.nih.gov/pubmed/32587697
http://dx.doi.org/10.1177/2050313X20932694
work_keys_str_mv AT hasegawamoto emergenceofundifferentiatedurothelialcarcinomaafterpembrolizumabtreatmentforpatientwithinvasiveurothelialbladdercanceracasereport
AT hasegawago emergenceofundifferentiatedurothelialcarcinomaafterpembrolizumabtreatmentforpatientwithinvasiveurothelialbladdercanceracasereport
AT ikedayohei emergenceofundifferentiatedurothelialcarcinomaafterpembrolizumabtreatmentforpatientwithinvasiveurothelialbladdercanceracasereport
AT haranoboru emergenceofundifferentiatedurothelialcarcinomaafterpembrolizumabtreatmentforpatientwithinvasiveurothelialbladdercanceracasereport
AT nishiyamatsutomu emergenceofundifferentiatedurothelialcarcinomaafterpembrolizumabtreatmentforpatientwithinvasiveurothelialbladdercanceracasereport

Ejemplares similares